[Intra-arterial infusion chemotherapeutic effect of stage III breast cancer by survival rates]. 1990

H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
1st Dept. of Surgery, Sapporo Medical College.

Between January 1977 and December 1989, 140 patients of Stage III breast cancer were treated in Sapporo Medical College. Sixty-six of these patients received intra-arterial infusion chemotherapy. The anticancer drugs were mainly given by two routes, infusion into the internal mammary artery and the subclavian artery. Continuous infusion of 5-FU and intermittent injections of ADR, MMC, 4'-epi-ADR or THP-ADR were jointly or individually made in each artery. The 5-and 10-year overall survival rates were: infusion group 49.2% and 49.2%, non-infusion group 64.0% and 45.0%, respectively. Intra-arterial infusion chemotherapy seems to be useful because non-infusion group contained mostly Stage IIIa and conversely the infusion group contained mostly Stage IIIb. A significant difference was seen between 5-FU infusion group and MMC.ADR group (p=0.026). MMC group, MMC + ADR combination group and 4'-epi-ADR group were marginally significantly different in terms of survival rates of the anticancer drugs of Stage IIIb.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival

Related Publications

H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
September 1997, Gan to kagaku ryoho. Cancer & chemotherapy,
H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
September 1970, Cancer,
H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
April 1980, Nihon Gan Chiryo Gakkai shi,
H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
September 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
September 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
February 2002, Gan to kagaku ryoho. Cancer & chemotherapy,
H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
August 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
September 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
February 1963, The Surgical clinics of North America,
H Masuoka, and K Asaishi, and K Toda, and A Okazaki, and K Yoshida, and S Ohba, and Y Watanabe, and H Sato, and M Okazaki, and M Mori
March 1963, The American journal of roentgenology, radium therapy, and nuclear medicine,
Copied contents to your clipboard!